PsychedelicNewsBreaks

ThursdayNov 03, 2022 11:14 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation Schedule for Upcoming Investor Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s Chief Executive Officer Doug Drysdale will present and host investor meetings at the Jefferies London Healthcare Conference taking place on Nov. 15-17, 2022. Drysdale’s presentation is slated to begin at 8:00 a.m. GMT on Nov. 15. Drysdale will also participate in a panel discussion titled “Psychedelics Landscape – What can we expect?” at 5:00 p.m. GMT on Nov. 16, 2022, at the Pinsent Masons Psychedelics Panel in London, U.K. In addition, Drysdale will participate in…

Continue Reading

TuesdayNov 01, 2022 12:58 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in Boston. Cybin director of neuropharmacology Amy Reichelt, PhD, will present during the event; her presentation, titled “CYB004 — Modifications to DMT to Enhance its Therapeutic Potential,” includes an overview of the preclinical data for CYB004, Cybin’s deuterated dimethyltryptamine (DMT) program and the advantages of deuteration on its therapeutic effect. Reichelt’s presentation will begin at 1:15 p.m. ET today.“I am delighted to be…

Continue Reading

ThursdayOct 27, 2022 11:47 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Delic Labs’ Participation at 11th Annual MJBizCon

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced details regarding Delic Labs CSO and President Dr. Markus Roggen’s participation at the MJBizCon in Las Vegas, Nevada, on Nov. 15, 2022. With more than 1,400 exhibitors, 35,000 attendees and countless networking opportunities, MJBizCon is the world’s premier cannabis business conference and tradeshow. At this year’s event, Dr. Roggen will participate in MJBizScience Symposium’s panel discussion entitled, “R&D as a Business Tool: Maximizing Revenue by Focusing on the Scientific Method.” Alongside leading industry professionals, Dr. Roggen will highlight the…

Continue Reading

ThursdayOct 27, 2022 11:36 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Graduates Class of Facilitators

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its EMBARK Psychedelic-Assisted Psychotherapy Training Program have announced the graduation of highly skilled facilitators who are now prepared to handle a range of experiences that participants of psychedelic-assisted psychotherapy may undergo. The training program includes foundational training enabling participants to learn the skills necessary to provide ethical care for and work with psychedelic-assisted psychotherapy patients. EMBARK is a leading-edge model of psychedelic-assisted psychotherapy that is implemented in Cybin’s phase 1/2a trial, which is designed to evaluate CYB003, Cybin’s investigational deuterated psilocybin analog. CYB003 has potential to…

Continue Reading

WednesdayOct 26, 2022 12:31 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Present at Largest Gathering in Psychedelic Medicine Sector

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its VP of R&D, James Kuo, M.D. M.B.A, will speak as a panelist at Wonderland: Miami, the largest business gathering in the psychedelic medicine sector. According to the update, Silo Pharma is a sponsor of the three-day event slated to take place Nov. 3-5, 2022, in Miami, Florida. Dr. Kuo will speak on the Mainstream Pharma and Psychedelics panel scheduled for Saturday, Nov. 5, on the Science Main Stage. “It will be an honor to join other industry leaders as…

Continue Reading

MondayOct 24, 2022 1:01 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions

Silo Pharma (NASDAQ: SILO) recently uplisted to the NASDAQ after the exciting progress it made over the last year. “Silo Pharma announced that it had successfully priced its fully underwritten initial public offering, raising gross proceeds of $5 million through the sale of one million shares of common stock,” reads a recent article. “Originally founded in 2010, Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Increasingly and over the past two decades, clinical research on psychedelics, most notably psilocybin and methylenedioxymethamphetamine…

Continue Reading

ThursdayOct 20, 2022 1:23 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Data Supporting SPC-14’s Therapeutic Potential for Alzheimer’s

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer’s disease, as demonstrated in a mouse model. According to the announcement, the research was conducted as part of a sponsored agreement with Columbia University in New York. “The result from these studies is a first step in the development of SPC-14 as a potential therapeutic for the treatment of Alzheimer’s,” said Silo Pharma CEO Eric Weisblum. “SPC-14 is a therapeutic that utilizes ketamine as one part of the…

Continue Reading

TuesdayOct 18, 2022 1:00 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement with Columbia University to Extend Research Pact

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered into an agreement with Columbia University to extend its current research partnership efforts. The agreement outlines certain assets that are currently under development regarding the work of associate professor of clinical Neurobiology Dr. Christine Ann Denny at Columbia University Irving Medical Center. Denny and her team are studying the molecular mechanisms underlying learning and memory, including diseases such as Alzheimer’s disease. According to the announcement, Denny’s pioneering research is evaluating whether ketamine and novel inventions associated with the substance have potential…

Continue Reading

MondayOct 17, 2022 1:36 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Continues Focus to Create the Best Psychedelic Therapies for Patients

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. “The in-human trial is critical to the company’s continued development of CYB003, a deuterated psilocybin analog that Cybin believes has potential to successfully address the challenges and limitations of oral psilocybin. According to the company’s preclinical research, CYB003 achieved less variability in plasma levels, along with faster onset of action, improved brain penetration, and shorter duration…

Continue Reading

TuesdayOct 11, 2022 11:25 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), The Chopra Foundation Note World Mental Health Day

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), joined partner The Chopra Foundation in recognizing World Mental Health Day, which was Monday, Oct. 11, 2022. The two organizations are working together to research the potential of psychedelic-based therapies for the treatment of mental health and to provide education about the use of psychedelics. Founded by Dr. Deepak Chopra, The Chopra Foundation is a not-for-profit organization dedicated to improving health and well-being. World Mental Health Day was designed to create an opportunity for those with mental health issues, along with advocates, governments, employers, employees and…

Continue Reading